Skip to content

Enterovirus- and parechovirus infection in Dutch children: epidemiology, diagnosis and prognosis

Enterovirus- and parechovirus infection in Dutch children: epidemiology, diagnosis and prognosis - Enterovirus- and parechovirus infection in children

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31728
Enrollment
240
Registered
2008-03-10
Start date
2008-03-18
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

common viral infection of the digestive system Enterovirus infection

Interventions

None listed

Sponsors

Sint Elisabeth Ziekenhuis
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: A + B are required;A. All Children =38,0°C ) 2. Meningeal inflammation: (anamnestic or with examination at least 2 of the following: headache, photophobia, nuchal rigidity, irritability, lethargy, nausea, vomiting, drowsiness, positive sign of Kernig or Brudzinsky) OR 3. At least 3 of the following: hypothermia, headache, drowsiness, nuchal rigidity, irritability, photofobia, vomiting, diarrhea, anorexia, couhing, myalgia, rash OR 4. Sepsis: Clinical suspicion of an infection plus: - temperature >38,5°C of 2 SD for age OR children 2 SD for age ;B. Signed informed consent by the parent(s)/legal guardian(s)

Exclusion criteria

Exclusion criteria: - Other proven cause of the infection: positive bacterial, viral (other than EV/HPeV), parasitic or fungal/yeast culture or PCR (feces, urine, throat swab, blood, CSF). - Other causes of illness: neoplasma, auto-immune diseases, rheumatic diseases, endocrinologic diseases, gastrooesophageal reflux, etcetera - Known psycho-motor retardation, metabolic diseases with neuro-muscular or cognitive abnormalities - Patients older than 16 years of age - No signed informed consent from the parent(s)/ legal Guardian(s)

Design outcomes

Secondary

MeasureTime frame
- Morbidity due to EV/HPeV infection (hospitalization, duration of hospitalization, duration and severity of symptoms, average school- and work absence, duration use of antibiotics) - Antibiotic treatment of patients (antibiotics, stop of antibiotics after diagnosis of EV or HPeV infection)

Primary

MeasureTime frame
- Specific clinical symptoms in patients with proven EV or HPeV infection - Different laboratory diagnostic methods: viral culture, PCR and serology - Several body fluids: feces, urine, throat swab, blood, and eventually CSF - Developmental milestones of children after an EV/HPeV CNS infection

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)